BCTX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

Stats
今日成交量	161 625
平均成交量	77 820.00
市值	22.21M
EPS	$0 ( 2024-03-20 )
下一个收益日期	( $-0.200 ) 2024-06-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.760
ATR14	$0.0150 (1.08%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-28	Bondarenko Jamieson	Buy	28 000	Common Shares
2022-12-23	Williams William V.	Buy	2 530	Warrant
2022-12-20	Bondarenko Jamieson	Buy	22 000	Common Shares
2022-08-01	Bondarenko Jamieson	Sell	0	Common Shares
2021-03-29	Bondarenko Jamieson	Sell	150 000	Option (Right to Buy)

INSIDER POWER
-65.20
Last 25 transactions
Buy: 52 530 \| Sell: 1 209 572

音量相关性

長: 0.04 (neutral)

短: -0.16 (neutral)

Signal:(50.275) Neutral

BriaCell Therapeutics 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

BriaCell Therapeutics 相关性 - 货币/商品

-0.28
( neutral )

-0.41
( neutral )

0.00
( neutral )

0.21
( neutral )

0.47
( neutral )

-0.33
( neutral )

BriaCell Therapeutics 财务报表

Annual	2023
营收:	$0
毛利润:	$-15 529.00 (0.00 %)
EPS:	$-1.300

FY	2023
营收:	$0
毛利润:	$-15 529.00 (0.00 %)
EPS:	$-1.300

FY	2022
营收:	$0
毛利润:	$-15 141.00 (0.00 %)
EPS:	$-0.750

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0900

Financial Reports:

No articles found.

BriaCell Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

BriaCell Therapeutics

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.